Speaker(s): 

 Justin Gregory, MD, MSCI, Physician, Pediatric Endocrinology, Vanderbilt University Medical Center-has disclosed the following: 

1. 1. Consultant: DRI Healthcare
   2. Scientific Advisory Board Member: Eli Lilly
   3. Scientific Advisory Board Member: vTV therapeutics
   4. Scientific Advisory Board Member: Sanofi

Moderator(s): 

Frank Maffei, MD, Chair, Pediatrics, JWCH, Geisinger - has nothing to disclose. 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Describe the disease dynamics of type 1 diabetes
• Define the drug's pharmacologic details
• Review data from key clinical trials
• Discuss delivery in clinical practice

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Frank Maffei, MD; Sarah Marks, MD; Amy Diehl, BSN, RN, CPN; Joan Keehan, RPH; Sandra Heller and Connie Winter have no identified disclosures. 

CE Committee Member/Content Reviewers, Thomas Urosevich, OD, MS, FAAO and Karen Tillotson, DHSc, PA-C have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPPA compliant. 

Commercial Support for this Session

None